Piper Sandler 2026

Hey all, wanted to get some insight into where Piper Sandler stands in the IB landscape heading into 2027.

Is Piper generally considered an established MM bank, or is it closer to the LMM? How does it stack up against other MM firms like HL, Blair, Baird, and Jefferies?

Is it a strong place to start an IB career in terms of deal experience and exit opportunities? Are exits to PE, private credit, or HFs realistic, or is Piper generally viewed as a step below other MM platforms?

Also curious which groups and offices are considered the strongest at Piper.

Would appreciate any honest takes from people familiar with the firm.

16 Comments
 

Incoming at a different MM from a semi target, Piper is definitely below the "Upper" MM firms including HL, Jeff, Blair, Baird although some groups at Piper likely outperform other MM banks. Cant speak to Piper much but know there Healthcare team is exceptional

 

From what I know, Piper Sandler is considered a solid middle-market bank but generally sits below the "upper" MM firms like HL, Jefferies, Blair, and Baird. Some teams, such as Healthcare, are exceptional, but overall deal volume and exit opportunities may not be as strong as at top MM banks. Still, for gaining diverse deal experience and potentially moving into PE or hedge funds, Piper can be a reasonable place to start.

 
Most Helpful

Incoming AN1 in healthcare at piper sandler, so keep that in mind. Here’s the general rundown:

Strongest groups at piper are healthcare (medtech probably best), FIG (though we call it FSG here), Tech (DBO Partners), and chemicals.  

Chemicals is relatively small group in NYC, and FIG is great but FIG groups generally don’t have great placements into buyout PE at any bank, so keep that in mind if that’s your goal. For large, accessible groups with strong traditional MM PE exits, healthcare is the way to go with tech also landing some great offers. That’s what i’ve seen. Of the 4 analysts i was close with above me, 1 exited to MM/UMM healthcare fund (7-10B AUM), one exited to a strong smaller MM healthcare fund (4-5B AUM), one left for a solid LMM generalist PE shop, and the last one left for an ops role at a portco of of PE megafund. 

Other groups are mostly mid-tier MM experience where good exits are harder to get. Good news is we’re extremely interested in growing/making acquisitions in our weaker groups rn (hence the PWP shenanigan) though, so in a few years things might shift. 

Ok, i’ve said my piece. Now everyone feel free to disagree and have at me.

 

Piper Houston should be in the discussion. One of the largest revenue contributors

 

Ut molestiae illo autem illo unde dolorum. Laborum error placeat eos quos laboriosam. Alias aspernatur illum quos est ipsa et autem. Et vitae quam ab rem nam sed voluptatem. Occaecati reprehenderit quos fugit.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”